MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab

Go back to MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
MACROGENICS (NASDAQ: MGNX) Delayed: 4.32 --0 (-0%)
Previous Close $4.32    52 Week High $36.11 
Open $4.32    52 Week Low $14.84 
Day High $4.32    P/E 11.08 
Day Low $4.32    EPS $0.39 
Volume 333